These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 7583554)

  • 1. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme.
    Tselepis AD; Dentan C; Karabina SA; Chapman MJ; Ninio E
    Arterioscler Thromb Vasc Biol; 1995 Oct; 15(10):1764-73. PubMed ID: 7583554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro.
    Karabina SA; Elisaf MC; Goudevenos J; Siamopoulos KC; Sideris D; Tselepis AD
    Atherosclerosis; 1996 Aug; 125(1):121-34. PubMed ID: 8831934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility.
    McCall MR; La Belle M; Forte TM; Krauss RM; Takanami Y; Tribble DL
    Biochim Biophys Acta; 1999 Jan; 1437(1):23-36. PubMed ID: 9931415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a).
    Lesnik P; Vonica A; Guérin M; Moreau M; Chapman MJ
    Arterioscler Thromb; 1993 Jul; 13(7):1066-75. PubMed ID: 8318508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copper-catalyzed oxidation mediates PAF formation in human LDL subspecies. Protective role of PAF:acetylhydrolase in dense LDL.
    Tsoukatos DC; Arborati M; Liapikos T; Clay KL; Murphy RC; Chapman MJ; Ninio E
    Arterioscler Thromb Vasc Biol; 1997 Dec; 17(12):3505-12. PubMed ID: 9437199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAF-acether-degrading acetylhydrolase in plasma LDL is inactivated by copper- and cell-mediated oxidation.
    Dentan C; Lesnik P; Chapman MJ; Ninio E
    Arterioscler Thromb; 1994 Mar; 14(3):353-60. PubMed ID: 8123638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor.
    Stafforini DM; McIntyre TM; Carter ME; Prescott SM
    J Biol Chem; 1987 Mar; 262(9):4215-22. PubMed ID: 3549727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma.
    Stafforini DM; Carter ME; Zimmerman GA; McIntyre TM; Prescott SM
    Proc Natl Acad Sci U S A; 1989 Apr; 86(7):2393-7. PubMed ID: 2928339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia.
    Karabina SA; Elisaf M; Bairaktari E; Tzallas C; Siamopoulos KC; Tselepis AD
    Eur J Clin Invest; 1997 Jul; 27(7):595-602. PubMed ID: 9263748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase.
    Dentan C; Tselepis AD; Chapman MJ; Ninio E
    Biochim Biophys Acta; 1996 Feb; 1299(3):353-7. PubMed ID: 8597590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein.
    Watson AD; Navab M; Hama SY; Sevanian A; Prescott SM; Stafforini DM; McIntyre TM; Du BN; Fogelman AM; Berliner JA
    J Clin Invest; 1995 Feb; 95(2):774-82. PubMed ID: 7860760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-density lipoprotein inhibits the production of platelet activating factor acetylhydrolase by HepG2 cells.
    Satoh K; Imaizumi T; Yoshida H; Takamatsu S
    J Lab Clin Med; 1994 Feb; 123(2):225-31. PubMed ID: 8301198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein.
    Stafforini DM; Tjoelker LW; McCormick SP; Vaitkus D; McIntyre TM; Gray PW; Young SG; Prescott SM
    J Biol Chem; 1999 Mar; 274(11):7018-24. PubMed ID: 10066756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier disease).
    Pritchard PH; Chonn A; Yeung CC
    Blood; 1985 Dec; 66(6):1476-8. PubMed ID: 4063532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet-activating factor acetylhydrolase and transacetylase activities in human plasma low-density lipoprotein.
    Tsoukatos DC; Liapikos TA; Tselepis AD; Chapman MJ; Ninio E
    Biochem J; 2001 Jul; 357(Pt 2):457-64. PubMed ID: 11439095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human plasma platelet-activating factor acetylhydrolase. Purification and properties.
    Stafforini DM; Prescott SM; McIntyre TM
    J Biol Chem; 1987 Mar; 262(9):4223-30. PubMed ID: 3558407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAF-acetylhydrolase, predominantly present in LDL in healthy subjects, is associated with HDL in a patient with LDL deficiency.
    Surya II; Mommersteeg M; Erkelens DW; Akkerman JW
    J Lipid Mediat; 1991; 3(1):27-38. PubMed ID: 1768838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contribution of individual lipoproteins to the degradation of platelet-activating factor in human serum.
    Ostermann G; Kostner GM; Gries A; Malle E; Till U
    Haemostasis; 1989; 19(3):160-8. PubMed ID: 2744632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia.
    Tsimihodimos V; Karabina SA; Tambaki AP; Bairaktari E; Miltiadous G; Goudevenos JA; Cariolou MA; Chapman MJ; Tselepis AD; Elisaf M
    J Lipid Res; 2002 Feb; 43(2):256-63. PubMed ID: 11861667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia.
    Guérin M; Dolphin PJ; Talussot C; Gardette J; Berthézène F; Chapman MJ
    Arterioscler Thromb Vasc Biol; 1995 Sep; 15(9):1359-68. PubMed ID: 7670950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.